Federal Register / Vol. 71, No. 203 / Friday, October 20, 2006 / Notices 61979 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10078] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

In compliance with the requirement 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Centers for Medicare & Medicaid 

Services (CMS), Department of Health 

and Human Services, is publishing the 

following summary of proposed 

collections for public comment. 

Interested persons are invited to send 

comments regarding this burden 

estimate or any other aspect of this 

collection of information, including any 

of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the Agency’s function; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Matching Grants 

to States for the Operation of High Risk 

Pools and Supporting Regulations at 42 

CFR 148.316, 148.318, and 148.320; 

Use: CMS is requiring this information 

as a condition of eligibility for grants 

that were authorized in the Trade Act of 

2002 (Pub. L. 107–210). The information 

is necessary to determine if a State 

applicant meets the necessary eligibility 

criteria for a grant as required by the 

law. The respondents will be States that 

have a high risk pool as defined in 

Section 2744(c)(2) of the Public Health 

Service Act. The grants will provide 

matching funds to States that incur 

losses in the operation of high risk 

pools. High risk pools are set up by 

States to provide health insurance to 

individuals that cannot obtain health 

insurance in the private market because 

of a history of illness. Form Number: 

CMS–10078 (OMB#: 0938–0887); 

Frequency: Reporting—On occasion; 

Affected Public: State, local, or tribal 

government; Number of Respondents: 

33; Total Annual Responses: 33; Total 

Annual Hours: 1,320. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, access CMS Web site 

address at http://www.cms.hhs.gov/ 

PaperworkReductionActof1995, or email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov, or call the 

Reports Clearance Office on (410) 786–

1326. 

Written comments and 

recommendations for the proposed 

information collections must be mailed 

or faxed within 30 days of this notice 

directly to the OMB desk officer: OMB 

Human Resources and Housing Branch, 

Attention: Carolyn Lovett, New 

Executive Office Building, Room 10235, 

Washington, DC 20503, Fax Number: 

(202) 395–6974. 

Dated: October 4, 2006. 

Michelle Shortt, 

Director, Regulations Development Group, 

Office of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. E6–17034 Filed 10–19–06; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10202] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

In compliance with the requirement 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Centers for Medicare & Medicaid 

Services (CMS), Department of Health 

and Human Services, is publishing the 

following summary of proposed 

collections for public comment. 

Interested persons are invited to send 

comments regarding this burden 

estimate or any other aspect of this 

collection of information, including any 

of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the Agency’s function; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

1. Type of Information Collection 

Request: New Collection; Title of 

Information Collection: Data Collection 

for Administering the Medicare Health 

Improvement Survey; Use: This 

beneficiary survey is to obtain 

information about beneficiary behavior, 

physical functioning and satisfaction 

with the care management programs 

data required to evaluate the Medicare 

Care Management for High Cost 

Beneficiaries demonstration (CMHCB). 

This demonstration provides an 

opportunity to test new models of care 

for Medicare beneficiaries who are highcost and who have complex chronic 

conditions with the goals of reducing 

future costs, improving quality of care 

and quality of life, and improving 

beneficiary and provider satisfaction. 

Form Number: CMS–10202 (OMB#: 

0938–New); Frequency: Reporting—On 

occasion; Affected Public: Individuals or 

Households; Number of Respondents: 

3633; Total Annual Responses: 3633; 

Total Annual Hours: 908. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, access CMS Web site 

address at http://www.cms.hhs.gov/ 

PaperworkReductionActof1995, or 

e-mail your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov, or call the 

Reports Clearance Office on (410) 786–

1326. 

Written comments and 

recommendations for the proposed 

information collections must be mailed 

or faxed within 30 days of this notice 

directly to the OMB desk officer: OMB 

Human Resources and Housing Branch, 

Attention: Carolyn Lovett, New 

Executive Office Building, Room 10235, 

Washington, DC 20503, fax number: 

(202) 395–6974. 

Dated: October 12, 2006. 

Michelle Shortt, 

Director, Regulations Development Group, 

Office of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. E6–17353 Filed 10–19–06; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Arthritis Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 


jlentini on PROD1PC65 with NOTICES
61980 Federal Register / Vol. 71, No. 203 / Friday, October 20, 2006 / Notices 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Arthritis 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 29, 2006, from 8 a.m. 

to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Pkwy., Gaithersburg, MD. 

Contact Person: Johanna M. Clifford, 

Center for Drug Evaluation and Research 

(HFD–21), Food and Drug 

Administration, 5600 Fishers Lane (for 

express delivery, 5630 Fishers Lane, rm. 

1093), Rockville, MD 20857, 301–827–

7001, FAX: 301–827–6776, e-mail: 

Johanna.Clifford@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512532. Please call the Information 

Line for up-to-date information on this 

meeting. The background material will 

become available no later than the day 

before the meeting and will be posted 

on FDA’s Web site at http:// 

www.fda.gov/ohrms/dockets/ac/ 

acmenu.htm under the heading 

‘‘Arthritis Advisory Committee.’’ (Click 

on the year 2006 and scroll down to the 

above named committee meeting). 

Agenda: The committee will discuss 

the safety and efficacy of the 

nonsteriodal anti-inflammatory drug 

(COX–2 inhibitor) new drug application 

(NDA) 20–998/S021, CELEBREX 

(celecoxib), Pfizer, Inc., for the proposed 

indication of the relief of the signs and 

symptoms of juvenile rheumatoid 

arthritis in patients 2 years and older. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 15, 2006. 

Oral presentations from the public will 

be scheduled between approximately 

11:30 a.m. and 12:30 p.m. Time allotted 

for each presentation may be limited. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 15, 2006. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Johanna 

Clifford at least 7 days in advance of the 

meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 13, 2006. 

Randall W. Lutter, 

Associate Commissioner for Policy. 

[FR Doc. 06–8787 Filed 10–19–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Neurological Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Postponement of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

The Food and Drug Administration 

(FDA) is postponing the meeting of the 

Neurological Devices Panel scheduled 

for October 31, 2006. The meeting was 

announced in the Federal Register of 

September 22, 2006 (71 FR 55491). 

FDA’s Center for Devices and 

Radiological Health will further 

evaluate data relevant to the topic. A 

future meeting date will be announced 

in the Federal Register. 

Contact Person: Janet L. Scudiero, 

Center for Devices and Radiological 

Health (HFZ–410), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 301–594–1184, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512513. Please call the Information 

Line for up-to-date information on this 

meeting. 

Dated: October 13, 2006. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. 06–8788 Filed 10–19–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Circulatory System Devices Panel of 

the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Circulatory 

System Devices Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 7 and 8, 2006, from 

8 a.m. to 5:30 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Salons A, B, and C, 

620 Perry Pkwy., Gaithersburg, MD. 

Contact Person: James Swink, Center 

for Devices and Radiological Health 

(CDRH) (HFZ–450), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 301–443–8262, 

ext. 163, or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 3014512625. Please call the 

Information Line for up-to-date 

information on this meeting. 

Agenda: The committee will discuss 

and make recommendations regarding 

issues related to stent thrombosis in 

coronary drug-eluting stents. 

Background information for the topic, 

including the agenda and questions for 

the committee, will be available to the 

public 1 business day before the 

meeting on the Internet at http:// 

www.fda.gov/cdrh/panel (click on 

Upcoming CDRH Advisory Panel/ 

Committee Meetings). 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 15, 2006. 

Oral presentations from the public will 

be scheduled on both days for 

approximately 1 hour at the beginning 

of committee deliberations and for 

approximately 1 hour near the end of 

the deliberations. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should notify the contact 


jlentini on PROD1PC65 with NOTICES